operating our Bob. fourth XXXX full-year to and conference results our everyone discuss Thanks, call highlights. Hey. financial the welcome to And and quarter
Commercial; our Parker, Doug our Levine, Science Chief my Officer; Medical who our Joining our Chief staff, Financial Sundar, me Chief Lyndal Dr. Al Padma Officer; newest our of Mitch is Operating today addition, Ross, are Dr. President Hesterberg, Officer; the Vice and Officer. Chief Senior
these of today. question-and-answer during available session will the All be folks
call, continued today's am decision July, to we've we've the how last made just say new confidently we last come. quarters. XXXX dedicated proud points providing to into role significant at start I wanted underserved along enter the can mission drive cancer assets value of enterprise To mission the to to OncoCyte's actionable answers progress our I several of expand reach Since organizational stepping the CEO our been and I with And acquisitions exciting have say years that in towards for and our continuum. velocity our growth and over
circumstances outbreak. like we facing COVID-XX we're the unprecedented acknowledge start, with before I'd the first But to also all
one much day As a and/or protect health you, a safety taking day patient therapy becomes every closer but I shelter that and And can from cancer treat. harder company, we in is the of metastatic a assure withheld that are every also place. doesn't lifesaving to step team, that recognize are disease procedure much, to to our
are So, patients those serve to of we meeting each dedicated we, remain physicians investors our day the at OncoCyte, and to who and our needs supporting vision.
actions in our the challenging and their workplace current support here communities the though, in taken important states families, complying by federal the government ensure to safety California of with and note, on restrictions are these It's times. and place in our to we the that employees, our
from during The another successful and our operating of XXXX. public uncertainty unprecedented use crisis is to lessons Clarient, financial of in company, team and we're today XXXX management our the learned navigation requires
measures these in operating our of you close rigorous essential, Let expenses that projects and of and oversight place. already assure will are prioritization me be
XX To our member minimize need together during the pitch OncoCyte times, to use come to these over the crisis. member with to the that in is challenging say of each can when enthusiasm. and beyond finally ensure we small responding our current next asking maintain of team hope challenge conviction incredible be to we'll I increase velocity days we're the our cash team every we with that
It's as national most that mandates. work essential types critical are an that of employees stay-in-place generally lab orders basis note is as-needed under staff important to the to services, and local our on and to perform support term or continuing defined
patients in ensure dedication the of cancer cause to for solutions in light cancer, patients. we advancing cancer We to outcomes we of to providing actual these remains contribute macroenvironment, bring real improve States. patients our will current leading death which healthier dedicated the that lung outcome remain our believe answers programs In United to for continually the
offerings noteworthy launch Before recent our is rolled growing the we into really I of dig into important family test. DetermaRx our now the branding. to highlight of our accomplishments, want we've as new This
of I'll of the today, that names call our comprehensive of across company to the new representative with the throughout new shift, each care begun we've website, is building a into introduce cancer transform this diagnostics stage believe how commercial We is offerings. So, our new lung continuum. suite along of a
to with cancer. of held in recent both discoveries history amount was which company done, So, our and of jumping a gotten into Genetics, with impactful of we've acquisition like the start work Insight lung privately a massive I'd breast
was This important ways. significant in very acquisition two OncoCyte for
I'll patients. DetermaIO. included about immunooncology the previously Immune potentially test, selection rebranded Score, a DetermaIO for diagnostic progress tell of our test is with in acquisition minute. cancer the for Modulation, you the or IM therapy a transformative significant This as proprietary And First, now
highlight to I'll which a in that services included operates immediately serve acquisition boutique value that customers. certified I that, to allows Genetics believe bring also successful tremendous also Insight of pharma scale business, that OncoCyte. before leverage the products Insight proprietary But lab our a biopharma will better to us
for biopharma growing base opportunities potential and scientific that companies, require is their the classes the for a us ultimately, leading-edge diagnostics which patients with right therapeutic clinical broader delivering commercial new by this important? use. and and is to their identify Why made being It provides trials, investment
gave expression test checkpoint acquisition from that therapies, to DetermaIO, individuals microenvironment identify Secondly, in responders evaluates that us the are to likely the immune or more cancer to known as access a respond patients also biopsies immune non-responders. to less gene and immunotherapy
use have do paradigm cancer. in late to of Checkpoint the how industry, inhibitors them. lot an transformed to as treatment stage we have work But a still on best lung
and in uniquely or the immune hot, the of as The active, characterizes the tumor is as DetermaIO to ability inflammatory microenvironment. test industry. the often in call surrounding test if or we dormant, in has tissue tumor context the this the In determine short, in it, cold infiltrates described around environment our
marketed tests predictive staining for As background, immune it, and – mutational or burden, call PDL-X quick two selection there therapy a affectionately currently TMB. as tumor diagnostic are we
for challenges both why our of and biomarkers This DetermaIO. room improvement. recognized with so widely these we're excited about plenty of are There is opportunity with
In in XXXX larger shown to clearly data superior set. tests. presented DetermaIO be in these a still be We sample available November, at SITC proven recognize two to needs outcome in was to this
more further extend work of So, underway tumors, solid believe to differentiate multiple across will types already this we diverse into larger, populations which DetermaIO. is
patients immune for have therapies oncology patients remains from community? Why that transformative pharmaceutical of likely the real While challenge for and both is been these so researchers. benefit it and are therapies a important identifying subset cancer a oncologists for to the patients,
have are Being which also by accurately allow And market. that treatment could will treating able on a speed it therapies. patients at benefit to can population brought new physicians helped to therapies more the accurately impact the predict these from to which patient will identify be real
Identifying that latent serious disorder have actual no therapy response. side potentially responders when is happen patients the autoimmune by that exacerbated minimizes in immune also the effects a
have of patient will as allow no private spending potentially alternative select for immune significant save use treatments judicious CMS therapy sustainable Well-informed, on impact to payers oncologists outcomes. as and well treatments, that
particularly given market that billion XXX,XXX close a addressable over Jama immune important therapy, to that estimated patients is testing representing US eligible total a the to of recent the patients. identify for appropriate This for are in $X publication
exceed for therapeutic grow the our therapy earlier-stage in therapies adjuvant immune approved Moreover, insurers this government settings. better help target could to years. patient potentially to burden as will billion future could cost DetermaIO predict are $XX population and immune which continue analysts spend reduce in
impact, X,XXX PDX improved to patients, are DetermaIO's PDLX patients. clinical the and outcomes potential for an Beyond is designed close There opportunity. to important trials services X.X ongoing million pharma over recruit
trials able to a patients identification Being may outperform be treatments improve allows appropriate and to and of them the truly qualification clinical transformative. for test potential that
that And this the us pharma owning break as pharma we positioned services opportunity. acquired Insight mentioned I compliant open to leaves earlier, Genetics well lab with
acquisition the incredibly I'm real be months since patients the how Given just of announcing made pharma, DetermaIO may progress for a important proud ago. we've of couple and
CLIA that validation we we to were thrilled week, of the DetermaIO. Last announce completed
for of biopharma With have available the CLIA we settings. research completion it validation, use making launched in and officially academic DetermaIO,
touching that American CLIA Briefly College acquired accredited in the Insight or in validation, what Pathologists, and of This CLIA which perform transaction. that upon out been XX sample call lab our we exceed pharmaceutical we multiple we CAP, lab testing. we ISO, ensures standards DetermaIO that qualified industry We're of get meet by clinical lab for or testing. diagnostic the for pharma top firms has and that proud clinical lab tests
PCR Europe, a solid we'll And DetermaIO pursuing the be characteristics of strategy of kit performance leading leveraging the install manufacturers. platform in test, based base the simultaneously on also Mark CE
diagnostic successful Providing when the been partners new our that have in in companion deployed happen not pharma we a a more test rapid can launched. the DetermaIO. And a potential large A to the central for EU have of we'll believe that for at test lab rapidly base since with make in across is democratized allows install ability work be here priority US Asia. or uptake ex-US strategies drugs
We've laboratory. obtained be come results So, the that successfully in potential what's DetermaIO? our confident partners next to for in shown can
Importantly, reproducible tissue the input. requires test is minimal and also highly
pharm actively our additional We to partners couldn't working meetings more in for upcoming is communities. This are with details an expect research exciting our present with beginning potential bio results medical new DetermaIO progress. engage pleased and the at on be we and and to
to the Razor prediction formerly DetermaRx, chemotherapy the benefit for with next patients genomics first in as test, non-small known lung Moving non-squamous cancer. cell test
risk patients gene expression DetermaIO, of low test patient's to a tumor non-small high early to analyzes recurrence. intermediate stage DetermaRx these Similar a cancer that stratify and cell lung into is
DetermaRx XX,XXX in lung underserved early diagnosis decision addresses over the for non-small X point plus stage cancer patients year. US or lung stage each a X very cancer cell with
of to complete treatment consists current which generally is intended The surgical paradigm resection, curative. be
XX% XX% recurrence die five will these of resection. from patients years within to early stage However, post
overall to potential many benefits, cancer provides from cost high-risk including recurrences early of non-small patients stage would morbidity outcomes, reduction patients survival over-treating of DetermaRx the treatment that expense patient lung identify Stratifying patients accompanies subset stage who improved benefit chemotherapy. by greatly the avoidance chemotherapy, of of late aims and preventing and that benefit from not toxic will and it. in cell
a study, increase that As with had post-surgery a reminder, identified a by rates. survival DetermaRx high in risk adjuvant patients brief significant were chemotherapy clinical treated in
in rate test XX% patients that patient had is of these as chemotherapy. the a been remarkable Specifically, not hard for to the high this market compared receive we've This risk XX% reason a get result in five-year the survival patients. did pushing and to group
a amount with last DetermaRx since accomplished We've call. significant our
County, foremost, the Florida we in DetermaRx of early Oncology. Precision Institute Orange commercial Hospital and announced at launch Cancer access Mission and Leonard with First our two sites, California,
total XX targets large all onboarded are weeks primary access are systems, multiple seven initial include hospitals share a health from XX now active care Dignity can sites states. part of that our Health have I into XX been customers and of launch, health major including the community-based seven and with Care, who in physicians Amazingly, early clinics a system commercial and of
customers we'll our over continue We on rapidly more strategically efforts growing the and next bring have a several to months. list believe
chemotherapy making most And DetermaRx, patient a excited of I'm treatment. physicians impact risk can already based change, of on administering seven what including We're made for results that patients high risk I as lives. Here's share an on recurrence. we've about treatment timely that, identified today's call, their high today. were
expand outcomes to is OncoCyte why of to that the we're that know test. The we reach potentially a real grow will improve ability I expect beginning impact our to thrilled have world we and I'm as patient joined now
will Recently, Rx a I've our been pandemic the about asked COVID-XX current launch. how lot affect
answer head just question on. me let So, that
access We response a was and to early prior the with sites. our launch phase solid And growing. have had outbreak the was terrific
excellent with hit team commercial a hired we know, you they As the running. and experience ground
reflect our range and of local, activities the adjust us, has engagement the Given current to marketing though, national COVID-XX, accounts target and state broad curtail to of environment. new our selling required responses to and face-to-face it
Our virtual now significantly ability is in to meet the oncology contacts. on with and community those relies reduced
high developing be where might cities believe delayed a will see lung until get cancer the surgeries rate trend we we better. in early stage situation Additionally, be incident
priorities maintain momentum their we to the healthcare as of education and serve, while as create possible, ensure for staff, much of have we To proactively physicians, a DetermaRx. virtual we respecting the communities worked the on patients environment their
be do US, for We physicians except cities from access of areas important these of are to our cases percentages most hit continue addressed speaking with greater the where know the being that early urgent hardest in delayed. surgeries
and though, happen The as thus possible. these is will removed, these soon reality, surgeries must tumors be as
early we new over our be eases. volume sites know we on our days, these when of while are access current the of are procedures, will XX need and So, we the growth patients customers sample to in bring trajectory ready next XX expecting serve to a and slowing life-saving situation
feedback patient conduct perspective, this has ordering education with extremely and patient to a ensure are been we to the actively patient test physicians early From continues. engaging positive to
In to addition, and at diagnosed saving, cancer. Foundation, risk lung with extending those GOX we dedicated organization the of have and the lives vulnerable, improving world's partnered leading with the
GOX our adoption test helping synergistic us the initiation and their education patient-facing Community across with are drive physician Foundation network to patient partnership, of Excellence Care These Center the efforts In programs. increase is also awareness. of help
and accredited, Gandara from what or which Davis feature renowned We have Johannes continuing CME we medical Dr. Kratz oncologists medical support provided David call Dr. for UC UCSF. world financial education, program, from an now
surgery rapidly initiated a we've are leader, with key despite the pathology in addition, ensure or setting speaker we in and peer-to-peer current test physician oncology, program a multi-specialty KOL, opinion and situation. our KOLs to In expanding education adoption
which cell of to the market. Medicare positive touch for shared proposed coverage now also Centers So, we last decision believe or On coverage Services, reimbursement. DetermaRx, anticipated cancer provide I Medicaid CMS, from non-small on XX% reimbursement may the a our and call, for for lung
like it. that to queue subsequent coverage have pricing will final are confirmed update contact they decision, we've that and or with at been come you LCD, our I'd and today awaiting the in with direct in CMS we dialogue local the currently
need determination the in current of now occur which for to the real seeking Given at CMS our DetermaRx situation companies COVID-XX was end we at to of to are their versus anticipating in related the the target, reimbursement test, respond of number the to XXXX LCD for the March. half time original sometime PCR first
We've for additional feedback received also XXX payer over together test. the continued and our have positive lives efforts the to supporting commercialization private plans overwhelmingly million by evidence reaching out cover that on
remember we will to the previous be to patient to from to pricing. the discussions are able able final important we our we once current It's CMS invoices that hold get orders and decision submit in from
targeted initial plan, populations beginning In to of expansion. we patients, addition focus commercialization explore with risk US an which that targeted to are represent international our on marketing initial a and regions is in the XX high highly also
the received regulatory that approval approval. in distribution to a I'm pleased first of our begin Canada, marking international DetermaRx regulatory say to we've
large ex-US labs addition, momentum our In forces continuing oncology sales be by we'll innovative existing international relationships. oncology-focused targeting and with
We remote believe for availability the in our the approach those building can geographies. this company themselves test, run a advance can drive and kit in labs of of that awareness demand potential
biopsies. all DetermaDx, to test started known biopsy lung malignancy in at it DetermaVu, potentially unnecessary transition formerly aid our in liquid as and where avoiding nodules Next, I'd development out to like to OncoCyte, lung ruling with invasive in
interrogation system immune DetermaDx of response the cancer. system's utilizes our presence immune that approach the harnesses proprietary to
last of that, DetermaDx. of our announced pleased CLIA call, on-track since study we the am say validation completion I our to
precision CLIA world was in our part approximately and specific conducted confirm reminder, tested a XXX setting. of and the in and lab staff of validation accuracy, when as lab validated the lab CLIA samples performance demonstrate real CLIA validation with reproducibility includes blood previously DetermaDx R&D As study, protocols test company's a tested goal to equivalent clinical the to
we do XXX the are validation If serve blinded, To test publications. successful, prior goal statistical lab to our validation blood launch. to the CLIA clinical our we clinical and confirmation completed, to clinical final DetermaDx create this, of will performance the deliver clinical samples validation to approximately the began testing patient solid with subsequently With setting. to prospectively establish the commercial as in collected independent lab power
includes in under the Since we lab all prior orders collected the at of pandemic clinical for the Once home patient as current will be the studies remain preparations the well California, have of the complete to samples publication QX. as we clin as which commercial which additional us begin. parameters of val CMS essential the stay by begin necessary we required to will we established, our workers COVID on clinical our that the availability, for submit track will end performance to qualify personnel and results, dossier, are current validation execution of
product this their submit we fortunate we're not fall, timeline dossier macroenvironmental our the that evolving normal. by process hopeful currently we're to to back and CMS Again, issues, plan when indeed impacted is is this
is, reimbursement submitted working to package Our and we're was assemble secure a for DetermaRx course, ultimate just broad of as what product. goal our to robust
through to very we X.X be and an diagnostic million to nodules With invasive play nodules of following an associated imaging, be more believe can complications. benign in procedure, detected has unnecessary DetermaDx these found majority reducing serious important with role biopsies, than annually lung which
corporate that great achieving On to are highlight, like things. front, to great philosophy key my the people I'd the again,
And this work who responsibilities departments despite but companies and macro are primary is in current We many on environment. track something incredibly the talented that moment. have small, facing our their stay us at a the help size team experienced, to across and the selflessly headwinds
Officer, addition Chief Ross. Group, Bethesda he at though, the in when Doug commitments with partners working Doug company wound where recent us a some our while of consulting our has is joined before July I Medical to staff, were OncoCyte. been since role important new Dr. joined the I One his down we
trained UCSF bandwidth We he Doug and years the discovering spent marketplace. shepherding are into and multivariate and has diagnostics XX past attention. pathology genomics pleased at his and us to full give the in has Stanford, the
to leading to extensive Thermo Technologies qualified uniquely our molecular Applied Genomics, valuable including experience company. perspective Molecular, and Clarient, at scientific and His Life companies, Fisher him commercial make medical, a GE bring diagnostic
and to main team Our growth California. relocation of commitment is recent Orange County, to for the our one reasons building actually
has Bay Our Alameda headquarters office new our replaced in the Area.
This for key relocation access growth County sciences grow for emerging Orange grow. the our life is the US, as our is to to talented an in with brings hub we that team as and individuals real
By we of moving confident CLIA with our reduce to Irvine, to support that trajectory operating growth to overall the we're talent continue ultimately notch our cost West and can facility. top Coast
community addition, community leveraging to Hope setting, of early with In us treatment Hospital. relocation the with Mission patients to allows the Center the along open Cancer centers, Hoag the Leonard reasonably Cancer City Institute our sites, access in including and engage at one of incredible DetermaRx Hospital,
ties the area that excited Orange bringing build community to by within patients. County We're we'll benefit strong may hopeful trials and contribute clinical I'm that
gotten treatment potential track, things. to DetermaIO, Taken got the months, paradigm for XXXX that and the it's In we've new is poised on DetermaRx lung all OncoCyte both dramatically the clear change cancer. we've to – do of together, have remarkable tests two DetermaDx exciting back nine
are these and Even setting. of care now commercially for Rx for IO academic use tests launched. research clinical two hard patient more, biopharma and the dedication, with and work and a lot
just the that I we the remains and today. and are of along number opportunities there underserved evaluating are said On value cancer could care believe last the on points our is and beginning decision call, continuum on I we ourselves true patients, partnerships to continually our and bringing believe shareholders. statement that value OncoCyte, how expand payers We're for this doctors, that
outcomes continuum, fast I'm treatment of providing across milestones committed cancer the with XXXX. progress by of mission at report care expect critical a to patient improving to accomplish as our continue the We accelerating of decision and goal actual paced decisions. optimizing our number significant we to And work answers in points
At this review Mitch to point, over for of the call I'd Mitch? a turn to our like Levine financials.
